Recombinant Human BTN2A1/Butyrophilin 2A1 Fc Avi Protein, CF

2 μg/lane of Biotinylated Recombinant Human BTN2A1 Fc Chimera Avi-tag Protein (Catalog # AVI10909) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 65-80 kDa to 130-160 kDa, respectively.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human BTN2A1/Butyrophilin 2A1 Fc Avi Protein, CF Summary

• Additional Information: Biotinylated
• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human CD277/BTN3A1 Fc Chimera Protein (Catalog # 8539-BT) is immobilized at 10.0 μg/mL, 100 μL/well, the concentration of Biotinylated Recombinant Human BTN2A1 Fc Chimera Avi-tag (Catalog #AVI10909) that produces 50% of the binding response is 1.00-6.00 μg/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human BTN2A1 protein
  

  Human BTN2A1 (Gln29-Ala248) Accession # Q7KYR7.3	IEGRMD	Human IgG1 (Pro100-Lys330)	Avi-tag
  N-terminus			C-terminus

• Accession #: Q7KYR7.3
• N-terminal Sequence: Protein identify confirmed by mass spectromety.
• Structure / Form: Disulfide-linked homodimer. Biotinylated via Avi-tag.
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Purity Statement: Antigen Affinity-purified
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity2
• Theoretical MW: 53 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 65-80 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after opening.
  • 3 months, -20 to -70 °C under sterile conditions after opening.
• Buffer: Supplied as a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human BTN2A1/Butyrophilin 2A1 Fc Avi Protein, CF

• BK14H9.1
• BT2.1
• BTF1
• BTF1BT2.1butyrophilin BTF1
• BTN2A1
• butyrophilin subfamily 2 member A1
• butyrophilin, subfamily 2, member A1
• DJ3E1.1
• FLJ36567

Background

Butyrophilin 2A1 (BTN2A1) is a type I transmembrane glycoprotein of the butyrophilin family within the Ig-superfamily. There are over 13 Butyrophilin and the closely related butyrophilin-like (BTNL) molecules and they have been identified as immune checkpoint receptors involved in modulating T cell function (1,2). Mature human BTN2A1 consists of an extracellular domain (ECD) with two immunoglobulin-like domains (one IgV and one IgC), a transmembrane segment, and a cytoplasmic region with a B30.2 domain (3). Alternative splicing generates additional isoforms of BTN2A1 that lack the first Ig-like domain or the transmembrane segment as well as isoforms with substitutions and deletions in the cytoplasmic region. BTN2A1 is widely expressed including on colonic epithelial cells, on immune cells, and in milk fat globules (4, 5). BTN2A1 binds to the C-type lectin DC-SIGN on monocyte-derived dendritic cells, and this interaction can be blocked by soluble gp130 from HIV (4). A polymorphism of BTN2A1 has been associated with metabolic syndromes, type II diabetes mellitus, chronic kidney disease, and hypertension (6, 7). Our Avi-tag Biotinylated BTN2A1 features biotinylation at a single site contained within the Avi-tag, a unique 15 amino acid peptide. Protein orientation will be uniform when bound to streptavidin-coated surface due to the precise control of biotinylation and the rest of the protein is unchanged so there is no interference in the protein's bioactivity.

1. Arnett, H.A. and J.L. Viney (2014) Nat. Rev. Immunol. 14:559.
2. Afrache, H. et al. (2012) Immunogenetics 64:781.
3. Tazi-Ahnini, R. et al. (1997) Immunogenetics 47:55.
4. Malcherek, G. et al. (2007) J. Immunol. 179:3804.
5. Cavaletto, M. et al. (2002) Proteomics 2:850.
6. Oguri, M. et al.(2011) J. Med. Genet. 48:787.
7. Horibe, H. et al. (2014) Mol. Med. Rep. 9:808.

Publications for BTN2A1 (AVI10909)(1)

Publication using AVI10909

• Billon, E;Imbert, C;Bruyat, D;Grassi, P;Robert, L;Fernez, T;Livrati, P;Ben Amara, A;Rouvière, MS;Richaud, M;Boucherit, N;Nunès, JA;Sabatier, R;Lambaudie, É;Chrétien, AS;Gravis, G;Gorvel, L;Olive, D; BTN2A1 acquisition through trogocytosis enhances V?9V?2 T cell cytotoxicity against autologous and cancer cells Cell reports 2025-10-07 [PMID: 41066236] (Mouse)

Bioinformatics

• Uniprot:
  • Q7KYR7.3()